2023年6月8日

公司汇集了证明团队和新技术来提高效率在抗体发现AbTherx Inc .私营生物技术公司与新技术,加速抗体的发现,宣布推出新一代的人类抗体发现的平台。AbTherx的小说转基因小鼠技术,Atlas老鼠,包括临床验证双特异性抗体格式最接近天然抗体抗体技术使用本机人力配置和长CDR3上序列,改善结果对具有挑战性的目标,如GPCRs和离子通道。AbTherx也增加获得转基因小鼠表达完整的人类抗体多样性。通过技术授权和研究合作,AbTherx各种规模的合作伙伴与药物开发人员克服最苛刻的挑战推进创新药物。AbTherx领导团队有超过100年的经验结合抗体的发现和转基因小鼠技术,包括HuMAb鼠标Medarex公司技术的发展和布里斯托尔迈尔斯哑炮(BMS)。HuMAb鼠标技术是世界上最成功的人类抗体发现平台,负责13个销售疗法。贾斯汀米卡,CEO,在高管和顾问的角色成功生物技术、药物发现平台,和医疗保健投资组织了15年。他最近的位置是AlivaMab发现服务的首席执行官,他领导的组织通过一个快速增长的时期。彼得位博士,全封闭,花了他的职业生涯关注clinical-grade人类抗体的发现,例如,Opdivo, Arzerra, Kesimpta,和著名的GPCR-targeting临床候选人,例如,Ulocuplumab (anti-CXCR4)和anti-CCR8抗体。彼得Medarex公司增长抗体发现单元在满足全世界的需求BMS的组织。 Dan Rohrer, PhD, CTO, has over 25 years of broad experience in antibody discovery. Over the last 20 years, Dan has specialized in creating human antibody discovery platforms, including developing the HuMAb Mouse platform - the preeminent platform based on FDA approvals. Additionally, Dan has an established background and publication record in GPCR biology and transgenic modeling. In addition to Mr. Mika, Dr. Brams, and Dr. Rohrer, AbTherx has attracted industry veterans Brian Conn as CFO, Catherine Kara as Head of IP, David Passmore as Head of Business Development, and Stacey Borders as Marketing and Communications Strategist. "It is exciting to launch this company and begin actualizing the positive impact we will have on the future of medicine," said Justin Mika, Chief Executive Officer of AbTherx. "Transgenic mouse technologies remain the most proven option for discovering and developing antibody therapeutics; however, there was room for improvement. Atlas Mice were thoughtfully designed to address legacy technology limitations and barriers." "Our prior experience developing, managing, and implementing transgenic technologies has allowed us to build a proprietary and scalable core technology with novel features that are particularly focused on enabling the needs of the modern drug generation market," said Dan Rohrer, Chief Technology Officer of AbTherx. "Atlas Mice can be rapidly adapted to meet the most pressing challenges in therapeutic antibody discovery and development; these tools are focused around native antibody structures, and the design principles are integrated with immunization and screening know-how to maximize discovery potential." Source: AbTherx, Inc